Jacob P Laubach

List of Publications by Citations

163 papers	6,880 citations	36 h-index	81 g-index
173 ext. papers	8,262 ext. citations	5.8 avg, IF	5.44 L-index

#	Paper	IF	Citations
163	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. *New England Journal of Medicine*, **2015**, 373, 1207-19	59.2	761
162	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. *New England Journal of Medicine*, **2016**, 374, 1621-34	59.2	684
161	Ibrutinib in previously treated Waldenstrm's macroglobulinemia. *New England Journal of Medicine*, **2015**, 372, 1430-40	59.2	617
160	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Leukemia*, **2012**, 26, 149-57	10.7	580
159	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. *Clinical Cancer Research*, **2015**, 21, 4607-18	12.9	214
158	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. *Lancet Oncology, The*, **2014**, 15, 1503-1512	21.7	207
157	Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. *Blood*, **2016**, 127, 2833-40	2.2	182
156	Resolving the daratumumab interference with blood compatibility testing. *Transfusion*, **2015**, 55, 1545-54	4.9	158
155	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. *Blood*, **2016**, 127, 681-95	2.2	154
154	Panobinostat for the Treatment of Multiple Myeloma. *Clinical Cancer Research*, **2015**, 21, 4767-73	12.9	150
153	The proteasome and proteasome inhibitors in multiple myeloma. *Cancer and Metastasis Reviews*, **2017**, 36, 561-584	9.6	150
152	Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. *Blood*, **2013**, 121, 1961-7	2.2	132
151	Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. *Blood*, **2011**, 117, 4409-19	2.2	125
150	Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. *Journal of Clinical Oncology*, **2011**, 29, 4243-9	2.2	107
149	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. *Blood*, **2014**, 123, 4136-42	2.2	102
148	Multiple myeloma. *Annual Review of Medicine*, **2011**, 62, 249-64	17.4	99
147	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. *Lancet Haematology,the*, **2020**, 7, e370-e380	14.6	98

146	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. *Blood Cancer Journal*, **2018**, 8, 109	7	97
145	Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. *Blood*, **2016**, 128, 1821-1828	2.2	82
144	New proteasome inhibitors in myeloma. *Current Hematologic Malignancy Reports*, **2012**, 7, 258-66	4.4	74
143	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. *British Journal of Haematology*, **2018**, 182, 222-230	4.5	70
142	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. *Blood*, **2011** , 118, 535-43	2.2	70
141	Current strategies for treatment of relapsed/refractory multiple myeloma. *Expert Review of Hematology*, **2014**, 7, 97-111	2.8	58
140	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. *Blood*, **2016**, 127, 2693-700	2.2	57
139	Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review. *JAMA Oncology*, **2017**, 3, 980-988	13.4	53
138	Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. *Seminars in Hematology*, **2009**, 46, 166-75	4	52
137	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. *Journal of Clinical Oncology*, **2020**, 38, 2380-2389	2.2	46
136	Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis. *Mayo Clinic Proceedings*, **2017**, 92, 1800-1805	6.4	45
135	Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. *British Journal of Haematology*, **2015**, 169, 851-8	4.5	44
134	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. *Journal of Clinical Oncology*, **2021**, 39, 757-767	2.2	43
133	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. *British Journal of Haematology*, **2015**, 169, 843-50	4.5	42
132	A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. *British Journal of Haematology*, **2018**, 180, 41-51	4.5	41
131	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. *Journal of Clinical Oncology*, **2021**, 39, 565-575	2.2	40
130	A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 344-353	12.9	39
129	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. *British Journal of Haematology*, **2017**, 178, 547-560	4.5	38

128	CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. *Clinical Cancer Research*, **2015**, 21, 2660-2	12.9	36
127	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. *Nature Communications*, **2020**, 11, 2996	17.4	34
126	Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015: Potential Underdetection of Cardiac Amyloidosis. *JAMA Cardiology*, **2018**, 3, 865-870	16.2	34
125	The evolution and impact of therapy in multiple myeloma. *Medical Oncology*, **2010**, 27 Suppl 1, S1-6	3.7	32
124	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. *Lancet Haematology,the*, **2020**, 7, e447-e455	14.6	32
123	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. *Lancet Oncology, The*, **2021**, 22, e105-e118	21.7	32
122	Ixazomib for the treatment of multiple myeloma. *Expert Opinion on Pharmacotherapy*, **2018**, 19, 1949-1968	4	32
121	Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update. *Blood*, **2019**, 134, 691-691	2.2	31
120	A Prospective Multicenter Study Of The Bruton's Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia. *Blood*, **2013**, 122, 251-251	2.2	29
119	Novel therapies in the treatment of multiple myeloma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2009**, 7, 947-60	7.3	28
118	Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. *Clinical Cancer Research*, **2014**, 20, 3955-61	12.9	27
117	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. *Haematologica*, **2020**, 105, 468-477	6.6	27
116	Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenstrm's Macroglobulinemia. *Leukemia and Lymphoma*, **2009**, 50, 694-702	1.9	26
115	Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone. *Blood*, **2016**, 128, 246-246	2.2	26
114	Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. *British Journal of Haematology*, **2018**, 181, 433-446	4.5	25
113	Management of myeloma-associated renal dysfunction in the era of novel therapies. *Expert Review of Hematology*, **2012**, 5, 51-66; quiz 67-8	2.8	25
112	Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma. *Blood*, **2014**, 124, 84-84	2.2	25
111	The power of proteasome inhibition in multiple myeloma. *Expert Review of Proteomics*, **2018**, 15, 1033-1052	4.2	25

110	Deacetylase inhibitors: an advance in myeloma therapy?. *Expert Review of Hematology*, **2017**, 10, 229-237	2.8	24
109	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. *American Journal of Hematology*, **2019**, 94, 1244-1253	7.1	24
108	Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. *Leukemia*, **2018**, 32, 1838-1841	10.7	24
107	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. *Future Oncology*, **2015**, 11, 1153-68	3.6	23
106	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. *British Journal of Haematology*, **2018**, 180, 821-830	4.5	23
105	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. *British Journal of Haematology*, **2018**, 182, 495-503	4.5	23
104	Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). *Blood*, **2011**, 118, 302-302	2.2	22
103	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. *Lancet Oncology, The*, **2021**, 22, 142-154	21.7	22
102	IgM myeloma: A multicenter retrospective study of 134 patients. *American Journal of Hematology*, **2017**, 92, 746-751	7.1	21
101	Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. *Expert Review of Hematology*, **2011**, 4, 51-60	2.8	21
100	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. *Hematology American Society of Hematology Education Program*, **2014**, 2014, 255-61	3.1	20
99	Management of relapsed and relapsed/refractory multiple myeloma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2011**, 9, 1209-16	7.3	20
98	Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. *Bone Marrow Transplantation*, **2018**, 53, 942-945	4.4	19
97	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. *Expert Review of Clinical Pharmacology*, **2016**, 9, 35-48	3.8	19
96	Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. *Pharmacological Research*, **2017**, 117, 185-191	10.2	19
95	Management of relapsed multiple myeloma after autologous stem cell transplant. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 793-8	4.7	19
94	Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. *Journal of Geriatric Oncology*, **2019**, 10, 486-489	3.6	19
93	A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. *Clinical Cancer Research*, **2019**, 25, 478-486	12.9	19

92	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. *Journal of Clinical Oncology*, **2021**, 39, 2430-2442	2.2	18
91	Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).. *Journal of Clinical Oncology*, **2014**, 32, 8513-8513	2.2	17
90	Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. *British Journal of Haematology* , **2018**, 180, 271-275	4.5	16
89	Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial. *Blood*, **2011**, 118, 480-480	2.2	15
88	Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma.. *Journal of Clinical Oncology*, **2013**, 31, 8512-8512	2.2	15
87	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. *Cell Reports*, **2021**, 34, 108532	10.6	15
86	Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. *British Journal of Haematology*, **2017**, 178, 756-763	4.5	14
85	Novel targeted agents in the treatment of multiple myeloma. *Hematology/Oncology Clinics of North America*, **2014**, 28, 903-25	3.1	14
84	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. *Hematology American Society of Hematology Education Program*, **2014**, 2014, 255-261	3.1	14
83	Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. *Blood*, **2018**, 132, 804-804	2.2	14
82	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. *Blood*, **2020**, 136, 45-46	2.2	13
81	Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. *Blood*, **2016**, 128, 976-976	2.2	13
80	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. *Leukemia and Lymphoma*, **2019**, 60, 118-123	1.9	12
79	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). *Blood*, **2013**, 122, 1969-1969	2.2	11
78	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. *British Journal of Haematology*, **2019**, 186, e35-e39	4.5	10
77	Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. *Blood*, **2008**, 112, 3696-3696	2.2	10
76	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). *Blood*, **2015**, 126, 3036-3036	2.2	10
75	Maintenance and continuous therapy for multiple myeloma. *Expert Review of Anticancer Therapy*, **2018**, 18, 751-764	3.5	9

74	The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. *Journal of Hematology and Oncology*, **2015**, 8, 37	22.4	9
73	Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma. *Blood*, **2019**, 134, 3178-3178	2.2	8
72	Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. *Leukemia*, **2018**, 32, 2032-2036	10.7	7
71	Clinical translation in multiple myeloma: from bench to bedside. *Seminars in Oncology*, **2013**, 40, 549-53	5.5	7
70	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2015**, 126, 4217-4217	2.2	7
69	Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. *EJHaem*, **2020**, 1, 94-102	0.9	6
68	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. *Blood*, **2018**, 132, 749-749	2.2	6
67	Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study. *Blood*, **2012**, 120, 336-336	2.2	6
66	Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. *Blood*, **2016**, 128, 3326-3326	2.2	6
65	Phase 1b study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.. *Journal of Clinical Oncology*, **2016**, 34, 8014-8014	2.2	6
64	Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. *Cancer Treatment and Research*, **2016**, 169, 145-167	3.5	6
63	Evaluating the adverse effects of melphalan formulations. *Journal of Oncology Pharmacy Practice*, **2019**, 25, 1631-1637	1.7	6
62	Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma. *Blood Cancer Journal*, **2021**, 11, 20	7	6
61	A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). *American Journal of Hematology*, **2021**, 96, 1595-1603	7.1	6
60	Bortezomib in the management of multiple myeloma. *Cancer Management and Research*, **2009**, 1, 107-17	3.6	5
59	A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma. *Blood*, **2019**, 134, 3169-3169	2.2	5
58	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. *Leukemia*, **2021**, 35, 3526-3533	10.7	5
57	Practical Considerations for Antibodies in Myeloma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2018**, 38, 667-674	7.1	5

56	Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba. *Blood*, **2019**, 134, 1906-1906	2.2	4
55	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety. *Blood*, **2019**, 134, 1898-1898	2.2	4
54	Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma. *Blood*, **2013**, 122, 1947-1947	2.2	4
53	MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.. *Journal of Clinical Oncology*, **2014**, 32, 8589-8589	2.2	4
52	Lack of Response to Vaccination in MGUS and Stable Myeloma.. *Blood*, **2009**, 114, 1852-1852	2.2	3
51	An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma. *Blood*, **2014**, 124, 2140-2140	2.2	3
50	Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia. *Blood*, **2014**, 124, 3081-3081	2.2	3
49	Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. *Blood*, **2017**, 130, 902-902	2.2	3
48	Resistance to Proteasome Inhibitors in Multiple Myeloma. *Resistance To Targeted Anti-cancer Therapeutics*, **2014**, 47-80	0.3	3
47	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 797-803	2	3
46	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in -Mutated Multiple Myeloma. *Clinical Cancer Research*, **2021**, 27, 6432-6444	12.9	3
45	74-Year-old female with new monoclonal protein on serum immunofixation electrophoresis. *Clinical Biochemistry*, **2018**, 51, 97-100	3.5	2
44	MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).. *Journal of Clinical Oncology*, **2013**, 31, 8584-8584	2.2	2
43	Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. *Blood*, **2014**, 124, 5777-5777	2.2	2
42	Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor Microenvironment Interactions.. *Blood*, **2010**, 116, 1574-1574	2.2	2
41	Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study. *Blood*, **2020**, 136, 4-6	2.2	1
40	Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. *Blood*, **2011**, 118, 1874-1874	2.2	1
39	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. *Blood*, **2011**, 118, 3966-3966	2.2	1

38	Molecular Analysis Of Circulating Tumor Cells Identifies Mutations That Are Distinct From Those Present In The Bone Marrow Of Patients With Multiple Myeloma. *Blood*, **2013**, 122, 533-533	2.2	1
37	Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. *Blood*, **2016**, 128, 2122-2122	2.2	1
36	Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. *Nature Cell Biology*, **2021**, 23, 1199-1211	23.4	1
35	Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma. *Blood*, **2014**, 124, 27-27	2.2	1
34	Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 752-765	2	1
33	A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. *Blood Cancer Journal*, **2021**, 11, 149	7	1
32	Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma. *Blood*, **2020**, 136, 25-26	2.2	0
31	A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41). *Blood*, **2021**, 138, 4776-4776	2.2	0
30	A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease. *Blood*, **2018**, 132, 1981-1981	2.2	0
29	A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study. *Blood*, **2016**, 128, 2117-2117	2.2	0
28	Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system. *Journal of Oncology Pharmacy Practice*, **2021**, 1078155221995885	1.7	0
27	Pomalidomide for the treatment of relapsed and refractory multiple myeloma. *Expert Opinion on Orphan Drugs*, **2014**, 2, 1089-1108	1.1	
26	Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study. *Blood*, **2020**, 136, 15-16	2.2	
25	Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma. *Blood*, **2021**, 138, 4082-4082	2.2	
24	A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Low Risk Smoldering Multiple Myeloma. *Blood*, **2021**, 138, 1659-1659	2.2	
23	B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma. *Blood*, **2021**, 138, 4782-4782	2.2	
22	Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen. *Blood*, **2018**, 132, 3234-3234	2.2	
21	A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. *Blood*, **2018**, 132, 3263-3263	2.2	

20	Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule. *Blood*, **2018**, 132, 2024-2024	2.2
19	CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias. *Blood*, **2018**, 132, 1367-1367	2.2
18	Improving Rates of Venous Thromboembolism Prophylaxis in Multiple Myeloma Patients on Immunomodulatory Drugs. *Blood*, **2018**, 132, 2235-2235	2.2
17	Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins. *Blood*, **2019**, 134, 318-318	2.2
16	Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy. *Blood*, **2019**, 134, 3091-3091	2.2
15	Mimicking Myeloma Niche Ex Vivo. *Blood*, **2014**, 124, 2076-2076	2.2
14	Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology. *Blood*, **2014**, 124, 3404-3404	2.2
13	Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. *Blood*, **2014**, 124, 2070-2070	2.2
12	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. *Blood*, **2016**, 128, 3276-3276	2.2
11	Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*, **2016**, 128, 2134-2134	2.2
10	A Pilot Study of Eltrombopag Plus G-CSF for Human CD34+ Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant. *Blood*, **2016**, 128, 5815-5815	2.2
9	Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function. *Blood*, **2010**, 116, 451-451	2.2
8	Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications. *Blood*, **2010**, 116, 5016-5016	2.2
7	Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. *Blood*, **2011**, 118, 815-815	2.2
6	RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,. *Blood*, **2011**, 118, 4134-4134	2.2
5	Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment. *Blood*, **2012**, 120, 565-565	2.2
4	Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma. *Blood*, **2012**, 120, 1812-1812	2.2
3	Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma.. *Journal of Clinical Oncology*, **2013**, 31, 8602-8602	2.2

2	Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.. *Journal of Clinical Oncology*, **2021**, 39, 12082-12082	2.2
1	Maximizing the clinical benefit of novel therapies in multiple myeloma. *Oncology*, **2009**, 23, 415-6, 419	1.8